PURPOSE: To investigate the efficacy of diffusion-weighted MRI (DWI) in differentiating recurrent tumor from chronic inflammation and fibrosis after cystectomy or transurethral resection of bladder cancer. METHODS: Eleven patients with suspected tumor recurrence underwent pelvic DWI and dynamic contrast-enhanced (DCE) MRI at 3 months to 7 years following bladder cancer resection. The diagnosis was histologically confirmed in all patients by transurethral or cystoscopic resection of 27 lesions within 2 weeks of MR examinations. RESULTS: The accuracies, sensitivities, specificities, and positive predict values of DWI (92.6%, 100%, 81.8%, and 88.9%) were higher than those of DCE MRI (59.3%, 81.3%, 27.3%, and 54.2%) for detecting recurrent tumors. Using receiver operating characteristic analysis, the accuracy of DWI was significantly higher than that of DCE MRI (P < 0.05). There was no significant difference between DWI diagnosis and histopathology (P > 0.05), whereas the difference between diagnosis of DCE MRI and histopathology was significant (P < 0.05). The normalized apparent diffusion coefficients of recurrent tumors (0.697 ± 0.219) were significantly (P < 0.05) lower than those of postoperative inflammation or fibrosis (1.019 ± 0.143). CONCLUSIONS: DWI is superior to DCE MRI for differentiating recurrent bladder tumors from postoperative inflammation or fibrosis. DWI can be included in the follow-up MRI protocol after bladder cancer surgery.
PURPOSE: To investigate the efficacy of diffusion-weighted MRI (DWI) in differentiating recurrent tumor from chronic inflammation and fibrosis after cystectomy or transurethral resection of bladder cancer. METHODS: Eleven patients with suspected tumor recurrence underwent pelvic DWI and dynamic contrast-enhanced (DCE) MRI at 3 months to 7 years following bladder cancer resection. The diagnosis was histologically confirmed in all patients by transurethral or cystoscopic resection of 27 lesions within 2 weeks of MR examinations. RESULTS: The accuracies, sensitivities, specificities, and positive predict values of DWI (92.6%, 100%, 81.8%, and 88.9%) were higher than those of DCE MRI (59.3%, 81.3%, 27.3%, and 54.2%) for detecting recurrent tumors. Using receiver operating characteristic analysis, the accuracy of DWI was significantly higher than that of DCE MRI (P < 0.05). There was no significant difference between DWI diagnosis and histopathology (P > 0.05), whereas the difference between diagnosis of DCE MRI and histopathology was significant (P < 0.05). The normalized apparent diffusion coefficients of recurrent tumors (0.697 ± 0.219) were significantly (P < 0.05) lower than those of postoperative inflammation or fibrosis (1.019 ± 0.143). CONCLUSIONS: DWI is superior to DCE MRI for differentiating recurrent bladder tumors from postoperative inflammation or fibrosis. DWI can be included in the follow-up MRI protocol after bladder cancer surgery.
Authors: Andrew B Rosenkrantz; Arjun V Balar; William C Huang; Kimberly Jackson; Kent P Friedman Journal: Clin Nucl Med Date: 2015-08 Impact factor: 7.794
Authors: V Hechler; M Rink; D Beyersdorff; M Beer; A J Beer; V Panebianco; M Pecoraro; C Bolenz; G Salomon Journal: Urologe A Date: 2019-12 Impact factor: 0.639
Authors: Andrew B Rosenkrantz; Kent P Friedman; Fabio Ponzo; Roy A Raad; Kimberly Jackson; William C Huang; Arjun V Balar Journal: Clin Nucl Med Date: 2017-01 Impact factor: 7.794
Authors: Sungmin Woo; Valeria Panebianco; Yoshifumi Narumi; Francesco Del Giudice; Valdair F Muglia; Mitsuru Takeuchi; Soleen Ghafoor; Bernard H Bochner; Alvin C Goh; Hedvig Hricak; James W F Catto; Hebert Alberto Vargas Journal: Eur Urol Oncol Date: 2020-03-19
Authors: Valeria Panebianco; Yoshifumi Narumi; Ersan Altun; Bernard H Bochner; Jason A Efstathiou; Shaista Hafeez; Robert Huddart; Steve Kennish; Seth Lerner; Rodolfo Montironi; Valdair F Muglia; Georg Salomon; Stephen Thomas; Hebert Alberto Vargas; J Alfred Witjes; Mitsuru Takeuchi; Jelle Barentsz; James W F Catto Journal: Eur Urol Date: 2018-05-10 Impact factor: 20.096